Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for CLN-978 (CD19xCD3) in Sjögren’s disease (SjD). The expected timing is based on the latest available company guidance and may change.
8/7/25- Currently enrolling following regulatory approval. 11/06/25:- OUTRACE SjD Ph1 study continues enrolling and treating patients. 01/08/26:- OUTRACE SjD Ph1 dosing ongoing; Part A initial safety and B cell data expected Q4 2026. 03/10/26:- OUTRACE SjD Ph1 Part A initial safety and B cell data planned Q4 2026. 05/07/26:- OUTRACE SjD Ph1 Part A initial data in Q4 2026 to include safety, B cells, biomarkers and preliminary activity. 08/06/26:- OUTRACE SjD Ph1 data expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.